Statins & Dementia: Research Breakthrough
- Stockholm-A new study indicates that statins, drugs prescribed to lower blood fat, could perhaps slow the cognitive decline associated with Alzheimer's disease in some individuals.
- The observational study compared data from over 15,500 dementia patients, nearly 11,000 of whom were treated with statins.
- Sara Garcia-Ptacek, a docent of neuroscience at the Department of Neurobiology, Care Sciences and Society, led the research.
Groundbreaking research suggests statins, commonly used to lower blood fat, may slow the progression of Alzheimer’s disease in some patients. This crucial finding, stemming from a study by the Karolinska Institutet, highlights a potential link between statin use and improved cognitive function. Analysis of over 15,500 dementia patients reveals that those taking statins demonstrated better cognitive scores. Importantly,a dementia diagnosis shouldn’t prevent statin treatment if necessary for managing high blood lipids. The study, published in _Alzheimer Research & Therapy_, underscores the need for further inquiry into statins and dementia, as researchers work to determine the precise impact of these drugs. This news,brought to you by News Directory 3,offers vital updates on medical breakthroughs. Discover what’s next as researchers plan clinical trials to confirm these findings.
Statins May Slow Alzheimer’s Progression, Study Suggests
Updated June 24, 2025
Stockholm-A new study indicates that statins, drugs prescribed to lower blood fat, could perhaps slow the cognitive decline associated with Alzheimer’s disease in some individuals. The research, spearheaded by the karolinska Institutet and published in Alzheimer Research & Therapy, suggests a possible link, though researchers emphasize the need for further investigation to confirm the role of statins in Alzheimer’s disease management.
The observational study compared data from over 15,500 dementia patients, nearly 11,000 of whom were treated with statins. Results showed that those on statins exhibited slightly better cognitive test scores, even with pre-existing conditions like high blood pressure, cardiovascular disease, and diabetes, all risk factors for dementia. However, the study cannot definitively prove a causal relationship between statin use and slowed cognitive decline.
Sara Garcia-Ptacek, a docent of neuroscience at the Department of Neurobiology, Care Sciences and Society, led the research. She emphasized that the findings do not constitute evidence that statins should be prescribed specifically for dementia. Though, she also noted that a dementia diagnosis should not preclude statin treatment if or else necessary for managing high blood lipids.
“People with Alzheimer’s dementia treated with statins had better cognitive development over time…if a person needs statins for high blood lipids,a dementia diagnosis should not stop the treatment,” Garcia-Ptacek said.
Garcia-Ptacek added that initial concerns existed regarding statins potentially causing confusion in dementia patients, leading to some reluctance in prescribing them. The research team’s initial hypothesis was that statins might slow dementia progression, prompting a broad investigation for supporting evidence.
What’s next
The researchers plan to conduct more precise cohort studies, potentially leading to clinical intervention studies to establish a causal link between statins and cognitive function in Alzheimer’s patients. The team aims to identify which patient groups benefit most from statins and why, before initiating clinical trials.